Cardiomyopathy of Friedreich ataxia

Journal of Neurochemistry

Volumn 126, Issue SUPPL.1, 2013, Pages 88-93

  Weidemann, Frank ^a   Störk, Stefan ^a   Liu, Dan ^a   Hu, Kai ^a   Herrmann, Sebastian ^a   Ertl, Georg ^a   Niemann, Markus ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

echocardiography; hypertrophy; typical features

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEFERIPRONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IDEBENONE; VERAPAMIL;

CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; FRIEDREICH ATAXIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART TRANSPLANTATION; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; PRIORITY JOURNAL; REVIEW; SODIUM RESTRICTION; SYMPTOMATOLOGY;

ECHOCARDIOGRAPHY; HYPERTROPHY; TYPICAL FEATURES;

CARDIOMYOPATHIES; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; FRIEDREICH ATAXIA; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING;

EID: 84880341815     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12217     Document Type: Review

References (31)

1. Dedobbeleer C., Rai M., Donal E., Pandolfo M., and, Unger P., (2012) Normal left ventricular ejection fraction and mass but subclinical myocardial dysfunction in patients with Friedreich's ataxia. Eur. Heart J. Cardiovasc. Imaging 13, 346-352.
2. Durr A., Cossee M., Agid Y., Campuzano V., Mignard C., Penet C., Mandel J. L., Brice A., and, Koenig M., (1996) Clinical and genetic abnormalities in patients with Friedreich's ataxia. N. Engl. J. Med. 335, 1169-1175.
3. Dutka D. P., Donnelly J. E., Nihoyannopoulos P., Oakley C. M., and, Nunez D. J., (1999) Marked variation in the cardiomyopathy associated with Friedreich's ataxia. Heart 81, 141-147.
4. Elliott P., and, McKenna W. J., (2004) Hypertrophic cardiomyopathy. Lancet 363, 1881-1891.
5. Friedman L. S., Schadt K. A., Regner S. R., Mark G. E., Lin K. Y., Sciascia T., St John Sutton M., Willi S., and, Lynch D. R., (2012) Elevation of serum cardiac troponin I in a cross-sectional cohort of asymptomatic subjects with Friedreich ataxia. Int. J. Cardiol. [Epub ahead of print].
6. Harding A. E., (1981) Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 104, 589-620.
7. Hart P. E., Lodi R., Rajagopalan B., et al,. (2005) Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up. Arch. Neurol. 62, 621-626.
8. Hewer R. L., (1968) Study of fatal cases of Friedreich's ataxia. Br. Med. J. 3, 649-652.
9. Jauslin M. L., Meier T., Smith R. A., and, Murphy M. P., (2003) Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J. 17, 1972-1974.
10. Kearney M., Orrell R. W., Fahey M., and, Pandolfo M., (2012) Antioxidants and other pharmacological treatments for Friedreich ataxia. Cochrane Database Syst. Rev. 1-27.
11. Koeppen A. H., (2011) Friedreich's ataxia: pathology, pathogenesis, and molecular genetics. J. Neurol. Sci. 303, 1-12.
12. Kosutic J., and, Zamurovic D., (2005) High-dose beta-blocker hypertrophic cardiomyopathy therapy in a patient with Friedreich ataxia. Pediatr. Cardiol. 26, 727-730.
13. Leonard H., and, Forsyth R., (2001) Friedreich's ataxia presenting after cardiac transplantation. Arch. Dis. Child. 84, 167-168.
14. Meyer C., Schmid G., Gorlitz S., et al,. (2007) Cardiomyopathy in Friedreich's ataxia-assessment by cardiac MRI. Mov. Disord. 22, 1615-1622.
15. Mottram P. M., Delatycki M. B., Donelan L., Gelman J. S., Corben L., and, Peverill R. E., (2011) Early changes in left ventricular long-axis function in Friedreich ataxia: relation with the FXN gene mutation and cardiac structural change. J. Am. Soc. Echocardiogr. 24, 782-789.
16. Pandolfo M., and, Pastore A., (2009) The pathogenesis of Friedreich ataxia and the structure and function of frataxin. J. Neurol. 256 (Suppl 1), 9-17.
17. Payne R. M., and, Peverill R. E., (2012) Cardiomyopathy of Friedreich's Ataxia (FRDA). Ir. J. Med. Sci. 181, 569-570.
18. Payne R. M., Pride P. M., and, Babbey C. M., (2011) Cardiomyopathy of Friedreich's ataxia: use of mouse models to understand human disease and guide therapeutic development. Pediatr. Cardiol. 32, 366-378.
19. Rajagopalan B., Francis J. M., Cooke F., Korlipara L. V., Blamire A. M., Schapira A. H., Madan J., Neubauer S., and, Cooper J. M., (2010) Analysis of the factors influencing the cardiac phenotype in Friedreich's ataxia. Mov. Disord. 25, 846-852.
20. Raman S. V., Phatak K., Hoyle J. C., et al,. (2010) Impaired myocardial perfusion reserve and fibrosis in Friedreich ataxia: a mitochondrial cardiomyopathy with metabolic syndrome. Eur. Heart J. 32, 561-567.
21. Regner S. R., Lagedrost S. J., Plappert T., et al,. (2012) Analysis of echocardiograms in a large heterogeneous cohort of patients with friedreich ataxia. Am. J. Cardiol. 109, 401-405.
22. Richardson D. R., (2003) Friedreich's ataxia: iron chelators that target the mitochondrion as a therapeutic strategy? Expert Opin. Investig. Drugs 12, 235-245.
23. Schulz J. B., Boesch S., Burk K., et al,. (2009) Diagnosis and treatment of Friedreich ataxia: a European perspective. Nat. Rev. Neurol. 5, 222-234.
24. Sedlak T. L., Chandavimol M., and, Straatman L., (2004) Cardiac transplantation: a temporary solution for Friedreich's ataxia-induced dilated cardiomyopathy. J. Heart Lung Transplant. 23, 1304-1306.
25. Silva M. C., Meira Z. M., Gurgel Giannetti J., et al,. (2007) Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J. Am. Coll. Cardiol. 49, 1874-1879.
26. Tsou A. Y., Paulsen E. K., Lagedrost S. J., Perlman S. L., Mathews K. D., Wilmot G. R., Ravina B., Koeppen A. H., and, Lynch D. R., (2010) Mortality in Friedreich ataxia. J. Neurol. Sci. 307, 46-49.
27. Unverferth D. V., Schmidt W. R. II, Baker P. B., and, Wooley C. F., (1987) Morphologic and functional characteristics of the heart in Friedreich's ataxia. Am. J. Med. 82, 5-10.
28. Weidemann F., Breunig F., Beer M., et al,. (2005) The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur. Heart J. 26, 1221-1227.
29. Weidemann F., Niemann M., Breunig F., et al,. (2009) Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 119, 524-529.
30. Weidemann F., Niemann M., Ertl G., and, Stork S., (2010) The different faces of echocardiographic left ventricular hypertrophy: clues to the etiology. J. Am. Soc. Echocardiogr. 23, 793-801.
31. Weidemann F., Rummey C., Bijnens B., et al,. (2012) The heart in Friedreich ataxia: definition of cardiomyopathy, disease severity, and correlation with neurological symptoms. Circulation 125, 1626-1634.